2024 Annual Report
Leadership and Governance
Guiding With Purpose
A Message from the President & CEO — Elise Huszar, MBA
As we reflect on 2024, I am proud to share the achievements of The Geneva Foundation over the past year. Our unwavering commitment to advancing military medical research has led to groundbreaking discoveries, strengthened collaborations, and reinforced our mission to improve the health and well-being of service members, veterans, and their families.
In 2024, Geneva supported more than 400 research programs across military treatment facilities, federal laboratories, and academic institutions worldwide. Our dedicated researchers and collaborators made significant strides in areas such as combat casualty care, biotechnology, and musculoskeletal injury (MSKI) care—ensuring those who serve receive the highest standard of medical innovation.
One major milestone was achieved through the Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) program, which in 2024 delivered a comprehensive 12-year analysis on the incidence, cost, and operational impact of MSKIs in the military.
Our Combat Casualty Care Operations Network (REC3ON) team at Madigan Army Medical Center advanced battlefield medicine through a new study on managing complex trauma cases in flight. The team also produced free, accessible training videos for deployed military medical teams—addressing a critical gap in care delivery in austere, airborne environments.
Initiatives such as the Autonomous Reanimation & Evacuation (AREVA) Research Institute & Innovation Center, the Sleep and Wearables Operational Research for Readiness and Defense (SWORD) program, and a pilot project implementing key elements of the Department of Defense’s Warfighter Brain Health Initiative in an elite Army unit have each contributed to advancing innovative medical solutions tailored to the needs of the warfighter.
Geneva also recognized Lt. Col. Andrew J. Sheean, MD, FAAOS as the 2023 Researcher of the Year for his pioneering work in orthopedic sports medicine, military readiness, and ACL recovery. His research is advancing evidence-based treatments that improve recovery outcomes and long-term musculoskeletal health for service members across the Military Health System.
Collaboration remains at the heart of our success. In 2024, Geneva collaborated closely with the medical community to support Department of Defense research priorities to improve medical outcomes for military personnel and their families. This was achieved through our strategic partnerships with industry leaders, non-profit organizations, and academic institutions aligned by a shared vision for innovation that accelerates the translation of research into practice. None of Geneva’s work would be possible without the passion and commitment of our exceptional staff and researchers, and the steadfast support of our Board of Directors, Scientific Advisory Board members, and sponsors. Your belief in our mission empowers us to push the boundaries of medical science and deliver transformative solutions where they are needed most.
Geneva remains steadfast in our pursuit of excellence, innovation, and impact. Together, we will continue to honor the service and sacrifice of our nation’s military by advancing medical research that saves lives and improves outcomes.
Thank you for being an integral part of our journey. We look forward to another year of progress and discovery.
With Gratitude,
Elise W. Huszar, MBA
President and Chief Executive Officer
Leadership Transition Marks a New Chapter for Geneva’s Board of Directors
After four years of dedicated service as Chair of Geneva’s Board of Directors, Neil Vining, MD, MBA, has passed the gavel to COL (R) Kent Kester, MD, USA. A long-time advocate for military medicine, Dr. Vining has played a vital role in Geneva’s growth and strategic direction, including its 30th anniversary milestone. Dr. Kester, who has served on Geneva’s Scientific Advisory Board since 2018 and as its Chair from 2021 to 2024, brings deep expertise in infectious disease research and military medical leadership. His appointment as Board Chair positions Geneva to continue its mission-driven impact under experienced and visionary guidance.
Read MoreGeneva Appoints Tom Ruggels, MBA, to Board of Directors to Bolster Strategic and Financial Leadership
Geneva welcomes Tom Ruggels, MBA, to its Board of Directors. A longtime supporter of Geneva’s mission, Mr. Ruggels brings over three years of financial expertise from the Finance Committee to help strengthen strategic leadership and advance military-focused research.
Read MoreDr. Stuart Tyner Joins Geneva’s Scientific Advisory Board to Advance Mission-Ready Infectious Disease Solutions
Dr. Stuart Tyner, former Director of the DHA Infectious Diseases Portfolio and the Military Infectious Diseases Research Program, joins Geneva’s Scientific Advisory Board. With extensive experience at the intersection of research, policy, and military medical readiness, Dr. Tyner will help guide Geneva’s work in accelerating requirements-driven solutions that strengthen force health protection and national defense. His insights will enhance Geneva’s ability to translate cutting-edge science into mission-ready capabilities, advancing our role as a trusted partner in the Military Health System.
Read More2024 Research & Development Highlights
Advancing Scientific Discovery
In 2024, Geneva advanced its mission to deliver deployable, dual-use medical solutions by supporting breakthrough research across cancer, infectious diseases, combat casualty care, and operational medicine. Guided by operational relevance and strategic collaboration, our work helped accelerate science into real-world capabilities that strengthen force readiness, enhance global health security, and expand the Military Health System’s ability to innovate at scale.
Geneva’s impact this year reflects its role as a trusted partner embedded within the nation’s defense medical research enterprise, aligning investigators, agencies, and industry to deliver results where they matter most.
Driving Force Readiness with Landmark MSKI Research
Geneva’s MIRROR program co-led a historic supplement in Military Medicine, spotlighting musculoskeletal injuries (MSKIs) in the U.S. Armed Forces. The eight-article publication, based on more than a decade of data spanning all military branches, delivers a comprehensive analysis of the incidence, cost, and impact of MSKIs. This foundational work equips the Military Health System with the evidence base needed to shape future policy, optimize rehabilitation strategies, and reduce injury-related readiness losses across the force.
Read MoreTranslating Research into Readiness — Combat Care in Transit
The Research for Combat Casualty Care Operations Network (REC3ON) team at Madigan Army Medical Center is translating research into real-world impact with a newly published study in the American Journal of Surgery—now actively shaping battlefield medicine. Funded by the U.S. Air Force’s 59th Medical Wing, the 2024 study focuses on Negative Pressure Wound Therapy (NPWT) and addresses a critical gap in trauma care during medical evacuation. To ensure broad accessibility and field utility, the research is accompanied by free training and troubleshooting videos—now available on the Deployed Medicine platform—to help deployed teams manage Wound Vacs effectively in austere, airborne environments.
Read MoreDr. Kathleen Cashman Leads Breakthrough Lassa Fever Vaccine Development
In a pivotal advancement for global health, Dr. Kathleen Cashman, a virologist and principal investigator with Geneva supporting USAMRIID, co-led a groundbreaking study to develop a vaccine candidate for Lassa fever, a deadly viral disease endemic to West Africa. Partnering with researchers from Thomas Jefferson University and the University of Maryland, Baltimore, Dr. Cashman helped advance LASSARAB, a novel vaccine built on a deactivated rabies virus platform.
The vaccine demonstrated strong protection against severe disease and death in preclinical trials. Dr. Cashman emphasized the devastating impact of Lassa fever and the critical need for safe, effective prevention. “Lassa fever is a very complex disease with few options for treatment. When you find something that can prevent people from developing severe disease and dying, that’s pretty astounding, and is exactly what is needed” she noted.
Backed by a $30 million NIH grant, the project has entered a Phase 1 clinical trial, offering hope to millions in regions where Lassa remains a persistent threat.
AREVA — A Year of Discovery and Impact
In 2024, the Autonomous Reanimation and Evacuation (AREVA) Research Institute and Innovation Center, led by Dr. Andriy Batchinsky, demonstrated exceptional research output in trauma care, critical care, and extracorporeal life support. The team produced eight peer-reviewed publications, delivered 10 conference presentations, and presented 14 scientific posters across a range of high-impact topics—from mobile extracorporeal support systems to pathogen eradication technologies. These efforts reflect AREVA’s commitment to advancing lifesaving medical innovations for both military and civilian use, especially in austere and resource-limited settings.
Read MoreBeyond the Front Lines: The Enduring Health Burden of Eye Injuries in U.S. Military Deployments
The study "Disability-Adjusted Life Years Resulting from Ocular Injury among Deployed Service Members, 2001–2020," co-authored by Geneva principal investigator Dr. Amanda Staudt, provides the first comprehensive estimate of the long-term health burden of eye injuries in deployed U.S. military personnel. By calculating over 11,000 disability-adjusted life years (DALYs), the research highlights the lasting impact of vision loss and blindness in combat, despite the low rate of permanent injury. The findings underscore the need for improved prevention, early intervention, and rehabilitation strategies, while offering critical data to inform policy and resource allocation in military eye trauma care.
Read MoreAwards and Recognitions
Saluting Innovation — Advancing Military Medical Research
Geneva’s investigators drive advancements that translate scientific discovery into operational impact, improving care, readiness, and recovery for service members and veterans. In 2024, Geneva researchers were recognized for influential contributions across trauma innovation, orthopedic recovery, and operational medicine. These honors reflect the depth of Geneva’s expertise and its commitment to accelerating solutions that serve those who stand ready.
Dr. Teryn Roberts Awarded Young Innovators Fellowship for Life-Saving Trauma Research
Dr. Teryn Roberts, Co-Principal Investigator at Geneva’s Autonomous Reanimation and Evacuation (AREVA) Research Institute & Innovation Center, received the Paul S. Malchesky ASAIOfyi Young Innovators Fellowship Award at the American Society for Artificial Internal Organs 70th Annual Conference for her abstract, Safe Utilization of a Nitric Oxide-Eluting ECLS System During 72 Hours of Veno-Venous ECCO₂R. Through AREVA’s pioneering translational research, Dr. Roberts’s work advances lifesaving technologies that address combat trauma and critical care needs, helping close critical gaps in battlefield survivability and emergency medicine.
Learn MoreLt. Col. Andrew J. Sheean
Recognized as 2023 Researcher of the Year
Lt. Col. Andrew J. Sheean, MD, FAAOS received Geneva’s 2023 Researcher of the Year Award for his pioneering contributions to orthopedic sports medicine, military medical readiness, and ACL recovery outcomes.
His work advances evidence-based treatments that strengthen force readiness, enhance service member recovery, and improve long-term musculoskeletal health across the Military Health System.
LTC (Ret.) Stephen DeLellis Celebrated for Distinguished Contributions to Special Operations Medicine
LTC (Ret.) Stephen DeLellis, PA-C, Executive Director of Geneva’s Fort Bragg Research Institute (FBRI), was inducted into the inaugural class of the Special Operations Forces Medical Hall of Honor at the 2024 Special Operations Medical Association (SOMA) Scientific Assembly. With 36 years of active-duty service—including over three decades with Army Special Operations Forces—Mr. DeLellis has advanced operational medicine through research leadership that addresses critical capability gaps for warfighters. His contributions continue t0 strengthen Geneva’s efforts to deliver precision-driven solutions for Special Operations Forces and the broader military community.
Learn MoreCollaborating with Government
Strengthening Readiness Through Partnership
In 2024, Geneva strengthened its role as a trusted government contractor, delivering specialized staffing and operational support for military and veteran health initiatives. From optimizing soldier performance on the ground to sustaining biomedical research that informs future care, Geneva’s government contracting work reflects its commitment to delivering agile, requirements-driven solutions that improve outcomes for service members, veterans, and the agencies that serve them.
Advancing Soldier Readiness through Holistic Health and Fitness (H2F)
The Geneva Foundation is proud to serve as a trusted teaming partner on Serco Inc.’s recently awarded $247 million U.S. Army Holistic Health and Fitness (H2F) System contract, which aims to enhance Soldier readiness and performance. As part of Team Serco—alongside HigherEchelon, Hyperion Biotechnology, and Resolution Think—Geneva brings deep expertise in military medical research and program management, making us a strategic asset in delivering impactful, multidisciplinary solutions. Our involvement in this high-visibility program underscores Geneva’s value as a mission-focused collaborator capable of supporting large-scale, integrated initiatives to advance warfighter health and performance.
Learn MoreSupporting Veteran-Focused Innovation with VA Puget Sound
Geneva continues its long-standing partnership with the VA Puget Sound Health Care System by providing expert staffing for the Animal Research Facility, enabling biomedical research that improves therapies, rehabilitation, and care standards for veterans. This collaboration supports the VA’s mission to deliver evidence-based care while accelerating innovations that directly benefit those who have served.
Learn MoreEconomic Impact
Fueling Real-World Change
In 2024, Geneva’s operational presence continued to generate a significant economic impact across our key regional hubs nationwide. Geneva strengthened economies through local procurement, workforce investment, and collaboration with regional businesses while supporting its mission to advance military medical research and readiness. This distributed economic footprint reflects Geneva’s commitment to operating close to its research partners, federal collaborators, and service members.
Geneva’s commitment to localized investment supports national security and health innovation and fuels regional economies. It also provides high-quality jobs, advances research infrastructure, and creates enduring partnerships across the United States.
Congressional Advocacy
Influencing Defense — Impacting Change
Geneva brings a unique and credible voice to defense advocacy, shaped by direct experience and embedded expertise. In 2024, our leadership engaged policymakers to champion military research priorities grounded in operational needs.
#TeamGeneva
United by Mission — Driven by Impact
At Geneva, our people are the driving force behind every research breakthrough, operational solution, and mission success. Guided by a shared commitment to innovation, integrity, and service, Geneva’s employees demonstrate every day what it means to align personal excellence with a national purpose. Their dedication strengthens our partnerships, accelerates our research, and delivers on Geneva’s promise to improve the health and readiness of those who serve.
Each year, the Wave the Flag award recognizes employees who exceed expectations and exemplify Geneva’s core values: innovation, quality, superior customer service, integrity, teamwork, and respect for all.
Their work embodies the spirit of #TeamGeneva—advancing science, strengthening partnerships, and serving with distinction at every level.
Our Operational Footprint
Measuring Mission — Magnifying Impact
In 2024, Geneva’s global research enterprise grew in scale, scope, and impact. Geneva advanced operationally relevant research programs that address critical gaps in military health and readiness through a diverse network of principal investigators, collaborators, and military performance sites. These numbers reflect the depth of Geneva’s commitment to accelerating innovation, strengthening force health protection, and delivering real-world solutions to service members, veterans, and the broader defense community.
Major Awards Funded in 2024
Driving Impact
In 2024, Geneva secured more than $45M in funding to support high-impact research aligned with the evolving needs of military medicine. These awards represent a cross-section of complex, mission-relevant projects advancing infectious disease countermeasures, warfighter recovery, brain health, and combat casualty care. Each initiative exemplifies Geneva’s role in accelerating innovation, enhancing readiness, and improving health outcomes for service members and the broader communities they serve.
Brain Health
Proof of Concept Pilot Project to Implement Elements of the Department of Defense Warfighter Brain Health Initiative in an Elite Army Unit
This pilot supports the DoD Warfighter Brain Health initiative by evaluating early detection and monitoring strategies for blast-related neurological impairments in elite Army units.
Principal Investigator: COL (Ret) Mark Ray
Funding Source: U.S. Army Medical Materiel Development Activity (USAMMDA) via MTEC
Impact: By integrating clinical, neurophysiological, and performance-based assessments, this study advances continuous brain health surveillance in Special Operations Forces. The findings will shape return-to-duty protocols, inform future technology acquisitions, and enhance long-term neurological readiness—benefiting both elite military personnel and broader brain health initiatives across the force.
Warfighter Recovery
Development of Patient-Matched Segmental Defect Implant System with Mechanobiologic Activation and Antimicrobial Coating for Treatment of Severe Fractures
This project develops a customizable implant system to support limb salvage in patients with severe fractures, integrating biomechanically adaptive design and antimicrobial protection.
Principal Investigator: Mitchell Greenberg, MEng
Funding Source: CDMRP Peer Reviewed Medical Research Program (PRMRP)
Impact: This innovative system aims to improve recovery and reduce infection risk following high-energy fractures—common in both combat and civilian trauma care. By enabling patient-specific implants that promote healing and prevent complications, the technology supports medical readiness for military personnel while also addressing critical needs in civilian orthopedic treatment.
Infectious Diseases
Efficacy Testing of a Marburg Virus Monoclonal Antibody Medical Countermeasure Candidate
This study evaluates the therapeutic potential of MBP091, a monoclonal antibody, against Marburg virus in a nonhuman primate model.
Principal Investigator: Dr. Sandra Bixler
Funding Source: Mapp Biopharmaceutical, Inc.
Impact: This research supports the development of a life-saving countermeasure for Marburg virus disease, a highly lethal and untreatable threat. By furthering evaluating MBP091’s efficacy, the study advances readiness for future outbreaks, and strengthens force protection for deployed service members exposed to high-risk environments. The findings also hold potential to benefit civilian pandemic preparedness and public health response.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50122C00076.
Musculoskeletal Injuries
PRECISe RTD Trial — PRECISion with Return to Duty Decisions in the Military
This study aims to validate a predictive algorithm to improve return-to-duty decisions following musculoskeletal injuries, reducing the risk of re-injury and supporting long-term force readiness.
Principal Investigator: Dr. Daniel Rhon
Funding Source: United States Army Medical Research Acquisition Activity (USAMRAA)
Impact: Musculoskeletal injuries are a leading cause of limited duty status among service members. This project delivers a data-driven tool that enhances the precision of return-to-duty decisions, reducing repeat injuries and preserving combat readiness. By accounting for the complex interplay of physical, psychological, and environmental factors, the study equips military providers with a practical solution to optimize recovery and performance. The validated model could also inform return-to-work strategies in civilian rehabilitation settings, offering a benefits across military and public health domains.
Combat Casualty Care
A Comprehensive DoDTR-Compliant Database of War-Related Injuries in Ukraine: Implications for Medical Support of Large-Scale Combat Operations with Near-Peer Adversaries
This project establishes a battlefield injury database in Ukraine using DoD Trauma Registry standards to inform U.S. military medical readiness for future large-scale combat operations.
Principal Investigator: Dr. Andriy Batchinsky
Funding Source: Medical Technology Enterprise Consortium (MTEC)
Impact: By capturing trauma data from real-world conflict conditions, this initiative provides actionable insights into injury patterns, treatment outcomes, and system-level gaps relevant to near-peer warfare. The result is a robust, interoperable dataset that can shape DoD medical planning, training, and resource allocation for high-intensity combat scenarios. The project also supports humanitarian collaboration and strengthens medical capabilities in austere environments—benefiting both military operations and global emergency response efforts.
Research Sites
Our Global Influence
Geneva supports military medical research at performance sites across the U.S. and worldwide, reinforcing its global impact on service member health, readiness, and innovation.
DoD and Federal Sites
Bassett Army Community Hospital
Alaska
Armed Forces Research Institute of Medical Sciences (USAMD-AFRIMS)
Bangkok
Naval Health Research Center (NHRC)
California
Naval Medical Center San Diego (NMCSD)
California
Evans Army Community Hospital (EACH)
Colorado
United States Air Force Academy (USAFA)
Colorado
Eisenhower Army Medical Center (EAMC)
Georgia
Fort Stewart
Georgia
Tripler Army Medical Center (TAMC)
Hawaii
Landstuhl Regional Medical Center (LRMC)
Landstuhl, Germany
National Heart, Lung, and Blood Institute (NHLBI)
Maryland
Naval Medical Research Command
Maryland
Uniformed Services University (USU)
Maryland
United States Army Center for Environmental Health Research (USACEHR)
Maryland
United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
Maryland
United States Naval Academy (USNA)
Maryland
Walter Reed Army Institute of Research (WRAIR)
Maryland
Walter Reed National Military Medical Center (WRNMMC)
Maryland
Naval Medical Center Camp Lejeune (NHCL)
North Carolina
United States Army Special Operations Command (USASOC)
North Carolina
Womack Army Medical Center (WAMC)
North Carolina
Fort Drum
New York
Keller Army Community Hospital (KACH)
New York
United States Military Academy (USMA)
New York
Marine Corps Recruit Depot, Parris Island (MCRD)
South Carolina
United States Army Medical Center of Excellence (MEDCoE)
Texas
Brooke Army Medical Center (BAMC)
Texas
Carl R. Darnall Army Medical Center (CRDAMC)
Texas
United States Army Institute of Surgical Research (USAISR)
Texas
Wilford Hall Ambulatory Surgical Center (WHASC)
Texas
William Beaumont Army Medical Center (WBAMC)
Texas
Alexander T. Augusta Military Medical Center (ATAMMC)
Virginia
Naval Medical Center Portsmouth (NMCP)
Virginia
Madigan Army Medical Center (MAMC)
Washington
Navy Medicine Readiness and Training Command Bremerton
Washington
VA Puget Sound Health Care
Washington
Sponsors and Collaborators
Cross-Functional Networks That Deliver Results
Geneva’s research success is made possible through the collaboration of more than 250 sponsors and partners across government, academia, industry, and nonprofit sectors. Their support strengthens our ability to accelerate innovation, translate research into real-world solutions, and advance the health and readiness of service members worldwide.
410 Medical, Inc.
4WEB Medical
89Bio
ABSS Solutions, Inc.
AGED Diagnostics
AMAG Pharmaceuticals, Inc.
AROA Biosurgery
ASAIO - American Society for Artificial Internal Organs
AbbVie
Advanced Technology International (ATI)
Akero Therapeutics
Albert Einstein College of Medicine
Aldeyra Therapeutics
Allucent
American CryoStem
Arena Pharmaceuticals
Arthroscopy Association of North America (AANA)
AstraZeneca
Attune Neurosciences
Avanos Medical, Inc.
Battelle
Bay Area Lyme Foundation
Baylor University
Boehringer Ingelheim
Boston Scientific
Bristol-Myers Squibb
CCI Research Foundation
CCJ Medical Devices, LLC
CSL Behring
CannonDesign
Celcuity
Celdara Medical
Celgene
Cereset
Children's Hospital Medical Center
Children's Oncology Group
Chiltern International, Inc.
CoachMePlus
Cofactor Genomics
Colorado State University
Congressionally Directed Medical Research Program (CDMRP)
Continuous Precision Medicine (CPM)
Cornell University
Critical Innovations
Culmen International
CymaBay Therapeutics
Daiichi Sankyo
Defense Advanced Research Projects Agency (DARPA)
Defense Medical Research and Development Program (DMRDP)
Digital Health Outcomes
Draper
Drowsy Digital, Inc.
Duke University
Emory University
Emovi
Empatica
EpicentRx
Evrys Bio
Expression
Eyedea Advertising & Design Studio
Ferring Pharmaceuticals
FibrenX
Florida Atlantic University
Florida State University
Foundation for Advancing Veterans' Health Research (FAVHR)
GE Global Research
GE HealthCare Technology & Innovation Center (HTIC)
GSK
Galera Therapeutics
Genentech
Genfit
GeoVax
Gilead Sciences
Glycominds
Greenphire
Hamilton Health Sciences
HighTide Therapeutics
Huxley Medical
ICF Incorporated
ICON
IQVIA
ImmunityBio
Indiana University
Insum Solutions Corp.
Integrated Biotherapeutics, Inc.
Integrum Scientific
InteraXon, Inc.
Intercept Pharmaceuticals
Inventiva Pharma
Irving Burton Associates
J. Craig Venter Institute
Johns Hopkins University
Johnson & Johnson Innovative Medicine
Johnson & Johnson Pharmaceutical Research & Development
KBRwyle
Kennel and Associates, Inc.
Kent Imaging
Kessler Foundation
Kitware
Kura Oncology
LSU Health Sciences Center
Lawrence Livermore National Security, LLC
Leidos
Level 42 AI
Lilly
Lutris Pharma
MESO Scale Diagnostics, LLC
MIMEDX
Madrigal Pharmaceuticals
Mahidol University
Manufacturers Alliance
Mapp BioPharmaceutical
Mass Eye and Ear
Massachusetts General Hospital
Mayo Clinic
MedStar Health Research Institute
Medical College of Wisconsin
Medical Technology Enterprise Consortium (MTEC)
Merck
Michigan State University
Microbiotix
Mitsubishi Tanabe Pharma
MyCardio, LLC
NGM Bio
NIRSense
National Football League Players Association (NFLPA)
National Institutes of Health (NIH)
NervGen Pharma
New Mexico Tech (NMT)
NorthSea Therapeutics B.V.
Novo Nordisk
NovoCure
Novogene
Oculogica
Odyssey
Oncternal Therapeutics
Oregon Health & Science University (OHSU)
PPD clinical research business of Thermo Fisher Scientific
PROTECT3D
PSI CRO
Pacira BioSciences
Parexel
Pfizer
PharPoint Research
Pharmaceuticals Research Associates (PRA)
PointCross Life Sciences
Primmune Therapeutics
ProPharma
Public Health Institute
RTI International
RadioRx
Regeneron
Research Foundation of SUNY
Rhode Island Hospital
RingTail Labs
Ripple Effect
Rochal Industries
Rutgers University
Safi Biotherapeutics
Salix Pharmaceuticals
Sanofi Pasteur
Sciperio
Seres Therapeutics
SiOxMed
Sparta Biomedical
Spaulding Rehabilitation Hospital
Spectrum Pharmaceuticals
Stanford University
Stumptown Research & Development
Syneos Health
TEDCO (Maryland Technology Development Corporation)
TFF Pharmaceuticals
TG Therapeutics
Takeda
Teledyne Scientific & Imaging
Texas A&M University
Texas Tech University
Texas Woman's University
The Catholic University of America
The Cleveland Clinic
The George Washington University
The International Inflammatory Bowel Disease Genetics Consortium (IIBDGC)
The Prometheus Group
The State University of New York
Thin Gold Line Solutions
Thomas Jefferson University
Tobira Therapeutics
UPMC
UT Health San Antonio
Uniformed Services University (USU)
United States Army Medical Research and Development Command (USAMRDC)
United States Department of Defense (DoD)
United States Department of Health and Human Services (HHS)
United States Department of Veterans Affairs (VA)
University of Alabama at Birmingham
University of California
University of Chicago
University of Cincinnati
University of Colorado
University of Florida
University of Georgia
University of Iowa
University of Kansas
University of Kentucky
University of Maryland - Baltimore
University of Miami
University of Minesota
University of Missouri
University of Montana
University of Nebraska
University of New Mexico Health Sciences Center
University of North Carolina - Greensboro
University of North Carolina at Chapel Hill
University of North Dakota
University of North Texas
University of Pittsburgh
University of Rhode Island
University of South Alabama
University of South Florida
University of Southern California
University of Texas at San Antonio
University of Utah
University of Virginia
University of Washington
University of Wisconsin - Madison
University of the Incarnate Word
Utah State University
Vanderbilt University Medical Center
Vapotherm
Virginia Commonwealth University
Virginia Tech
Wake Forrest University
Wayne State University
Western Michigan University
Yale University
Zeel
Zydus Pharmaceuticals
zCore Business Solutions, Inc.
Financial Overview
Investing in Our Mission
